IceCure Medical (ICCM) Q1 2026: North America Sales Surge 84% as FDA Clearance Unlocks Adoption
FDA clearance for ProSense in low-risk breast cancer catalyzed a decisive inflection in U.S. and global demand, driving rapid account expansion and sales momentum. Commercial and clinical engagement is accelerating, with a robust pipeline and reimbursement tailwinds positioning ICCM to scale adoption through 2026. Management’s focus on execution and physician network penetration signals a durable growth phase, though procedural ramp and reimbursement timing remain critical watchpoints.
Summary
- Regulatory Validation Accelerates Commercialization: U.S. FDA clearance triggered a step-change in physician adoption and customer activity.
- Pipeline Conversion Drives Recurring Revenue Visibility: Strong lead generation and procedural growth are translating into system placements and disposable sales.
- Durability Hinges on Reimbursement and Clinical Evidence: Ongoing CPT code progress and real-world data are key to sustaining momentum.
Business Overview
IceCure Medical develops and commercializes ProSense, a minimally invasive cryoablation system for the treatment of tumors, primarily in breast, kidney, and lung tissue. The company generates revenue through system sales and recurring disposable probe sales, with the U.S. breast cancer market as its strategic focus. Major segments include the U.S., North America ex-U.S., and international markets, with procedural volume and new account activations as core revenue drivers.
Performance Analysis
Revenue growth of 26% year-over-year in Q1 2026 was underpinned by a dramatic 84% surge in North America sales, with U.S. sales up 31% as both system placements and disposable probe utilization rose. This reflects the first full quarter of commercial activity following FDA clearance for ProSense in low-risk early breast cancer, a pivotal regulatory milestone that expanded the company’s total addressable market and unlocked new customer segments.
The active account base expanded from 13 to 19 post-clearance, marking a 46% increase and demonstrating tangible pipeline conversion as previously dormant sites reactivated and new institutions onboarded. Growth was broad-based, spanning prestigious hospital networks, regional systems, and outpatient clinics, with procedural activity rising at both new and existing sites. This operational breadth is critical for recurring revenue generation, as higher procedure volumes drive ongoing disposable sales.
- Procedural Momentum: Utilization growth at both new and legacy accounts is supporting recurring revenue and indicating early adoption traction.
- Lead Generation Inflection: Qualified leads from major U.S. conferences post-clearance significantly outpaced 2025 levels, feeding a robust sales funnel into late 2026 and early 2027.
- Geographic Expansion: FDA clearance is catalyzing renewed interest internationally, especially in Europe and Asia, amplifying the global opportunity even where CE Mark was already held.
While the U.S. remains the primary growth engine, international markets and multi-organ applications (notably kidney and lung outside the U.S.) provide additional diversification and upside. Management’s commentary and Q&A responses reinforce the durability of the current growth trajectory, but also highlight the importance of reimbursement progress and procedural ramp for sustained performance.
Executive Commentary
"Our results clearly demonstrate high skills accelerating commercial momentum, particularly in the U.S., following FDA clearance for low-risk early breast cancer, the continued conversion of our growing pipeline in your active customers, and the expanding clinical and scientific validation supporting process."
Al Shamir, Chief Executive Officer
"We are seeing a clear and meaningful acceleration in demand for ProSense across the U.S., driven by several converging factors...The leads generated following FDA clearance are now progressing through purchasing processes and are expected to convert into system sales and installation this quarter and over the following quarters."
Shad Good, VP of Sales, North America
Strategic Positioning
1. FDA Clearance as Commercial Catalyst
Regulatory validation for ProSense in low-risk breast cancer is the single most important driver of adoption, unlocking pent-up demand and reactivating previously dormant accounts. This milestone has also elevated the company’s profile at major medical conferences, generating unprecedented lead flow and positioning ICCM as a category-defining innovator.
2. Recurring Revenue Model through Procedural Growth
System placements are increasingly paired with rising disposable probe sales, reflecting successful integration of ProSense into clinical workflows. The shift toward outpatient and office-based procedures, combined with growing procedural volume, enhances visibility into future recurring revenue streams and customer stickiness.
3. Reimbursement Expansion as Adoption Lever
ICCM is actively pursuing CPT-1 code reimbursement for physician fees (expected submission in June, potential approval for 2028) and has applied for transitional pass-through payments. Facility costs are already covered, enabling commercial activity, but expanded reimbursement will be critical for broader penetration and physician economic alignment.
4. Post-Market Clinical Evidence and Academic Engagement
The CHOICE post-market study (30 hybrid sites) and a growing body of investigator-initiated research provide real-world data to reinforce efficacy and safety, supporting both regulatory expansion and clinical guideline inclusion. This academic momentum is unique for a single system and will be essential for broader physician buy-in.
5. Global and Multi-Organ Opportunity
FDA clearance has had spillover impact internationally, with increased interest in Europe and Asia for both breast and other organ indications. The company is concurrently pursuing regulatory approvals in Canada and Japan, and continues to treat kidney and lung cancers in non-U.S. markets, diversifying its growth avenues.
Key Considerations
ICCM’s Q1 2026 marks a pivotal transition from regulatory foundation to commercial execution, with a clear focus on scaling adoption and recurring revenue. The company’s ability to convert leads, expand reimbursement, and deepen clinical evidence will shape its growth profile over the next 12-24 months.
Key Considerations:
- Sales Force Expansion: New U.S. sales hires are expected to accelerate penetration of key accounts and support pipeline conversion.
- Reimbursement Milestones: CPT-1 code submission and pass-through payment applications are underway, but timelines for broader reimbursement remain extended.
- Procedural Ramp Pace: While active accounts are growing, the cadence of procedural adoption and utilization per site will be a key metric to watch.
- International Regulatory Progress: Approvals in Canada (expected by year-end) and Japan (submission targeted soon) could open new revenue streams and validate global demand.
- Clinical Guideline Inclusion: Updated 2026 American Society of Breast Surgeons guidelines now recommend cryoablation for select patients, supporting mainstream adoption.
Risks
Commercial ramp is partly contingent on the pace and breadth of reimbursement expansion, especially for physician fees. Delays in CPT-1 code approval or pass-through payments could slow adoption in certain settings. Competitive dynamics in minimally invasive oncology and procedural inertia among clinicians may also temper near-term growth. International regulatory timelines are subject to local agency feedback and could introduce variability in global opportunity realization.
Forward Outlook
For Q2 2026, ICCM expects:
- Continued growth in active accounts, with additional system sales and installations anticipated as pipeline leads convert.
- Ongoing procedural growth at both existing and new sites, driving recurring disposable revenue.
For full-year 2026, management maintained a growth trajectory outlook:
- Further expansion of the U.S. commercial footprint and sales force.
- Milestone progress on CPT-1 code and pass-through reimbursement applications.
Management highlighted several factors that will shape the year:
- Durability of demand as procedural adoption scales beyond early adopters.
- Impact of expanded clinical data from the CHOICE study and ongoing investigator-initiated trials.
Takeaways
ICCM’s Q1 2026 performance validates the commercial inflection unlocked by FDA clearance, with strong sales, pipeline visibility, and broadening clinical engagement. The company’s focus on reimbursement, evidence generation, and sales force scale will be decisive as it seeks to build a durable recurring revenue business.
- Commercial Inflection: FDA clearance transformed U.S. demand and pipeline conversion, with active accounts up 46% and broad procedural adoption underway.
- Execution Focus: Sales force expansion and reimbursement initiatives are well-timed to sustain momentum, but the procedural ramp and payor alignment will determine trajectory.
- Future Watchpoints: Investors should track procedural volume per site, CPT-1 code progress, and international regulatory milestones as leading indicators of sustained growth and competitive positioning.
Conclusion
ICCM enters a new phase of commercial execution, leveraging regulatory wins and clinical validation to drive rapid adoption in the U.S. and abroad. The durability of growth will depend on the pace of procedural ramp, reimbursement expansion, and continued clinical evidence generation. The strategic foundation is strong, but execution and payor progress remain critical for long-term value creation.
Industry Read-Through
ICCM’s Q1 2026 results highlight a broader industry shift toward minimally invasive, office-based oncology interventions, with regulatory validation serving as a key commercial unlock. The rapid pipeline conversion and procedural adoption seen here signal a playbook for medtech innovators targeting underpenetrated indications. Reimbursement expansion and real-world evidence generation are emerging as critical levers for category growth, with implications for competitors in the ablative therapy and interventional oncology space. The spillover of U.S. regulatory milestones into international markets underscores the globalizing nature of medtech adoption cycles.